Regular Articles
Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits

https://doi.org/10.2353/ajpath.2006.060002Get rights and content

Tau transgenic mice are valuable models to investigate the role of tau protein in Alzheimer's disease and other tauopathies. However, motor dysfunction and dystonic posture interfering with behavioral testing are the most common undesirable effects of tau transgenic mice. Therefore, we have generated a novel mouse model (THY-Tau22) that expresses human 4-repeat tau mutated at sites G272V and P301S under a Thy1.2-promotor, displaying tau pathology in the absence of any motor dysfunction. THY-Tau22 shows hyperphosphorylation of tau on several Alzheimer's disease-relevant tau epitopes (AT8, AT100, AT180, AT270, 12E8, tau-pSer396, and AP422), neurofibrillary tangle-like inclusions (Gallyas and MC1-positive) with rare ghost tangles and PHF-like filaments, as well as mild astrogliosis. These mice also display deficits in hippocampal synaptic transmission and impaired behavior characterized by increased anxiety, delayed learning from 3 months, and reduced spatial memory at 10 months. There are no signs of motor deficits or changes in motor activity at any age investigated. This mouse model therefore displays the main features of tau pathology and several of the pathophysiological disturbances observed during neurofibrillary degeneration. This model will serve as an experimental tool in future studies to investigate mechanisms underlying cognitive deficits during pathogenic tau aggregation.

Cited by (0)

Supported by the Centre National de la Recherche Scientifique; the Fédération pour la Recherche sur le Cerveau; Gis-Longévité; the Institut National de la Santé et de la Recherche Médicale; the European Community (an integrated project for abnormal proteins in the pathogenesis of neurodegenerative diseases, LSHM-CT-2003-503330 and a Marie Curie Fellowship K.S.); the Association d'Etudes et de Recherche sur la Maladie d'Alzheimer; the International Alzheimer Research Foundation (to J.P.B.); and the Région Nord/Pas-de-Calais and Centre Hospitalier Régional Universitaire-Lille (scholarship to A.B.).

A.B. and K.L. contributed equally to this study.

Mice for this study were generated in collaboration with Günter Tremp and Nathalie Touchet from Sanofi-Aventis, Vitry-sur-Seine, France.

Supplemental material for this article can be found on http://ajp.amjpathol.org.

View Abstract